CD8A and acute myeloid leukemia: Based on the previous pre-clinical studies, we demonstrate NKT cell-licensed DC therapy integrating innate and adaptive immunity against relapse and refractory AML with safety in first-in-human study, and this can also induce the reinvigoration of pre-existing pre-exhausted T cells and the emergence of newly activated CD8+ T cells.